CHICAGO — If ENDO 2025 signaled that incretin peptides had moved from specialty endocrinology into mainstream medicine, ENDO 2026 confirmed they now define the conference itself. From the opening plenary on June 13 through the final poster teardown on June 16, McCormick Place was dominated by GLP-1 receptor agonists, dual GIP/GLP-1 co-agonists, and the first large-scale presentation clusters devoted to triple-agonist molecules that also engage glucagon receptors.
Registration figures released by the Endocrine Society put attendance above 8,200—a record for the post-pandemic cycle—with obesity pharmacology and cardiometabolic peptide tracks accounting for roughly a third of session bookings. Several exhibitors on the show floor reported running out of analytical method brochures by the second day, a small but telling indicator of how many laboratory and CRO teams were scouting reference materials and assay guidance alongside clinicians.
Plenary focus: beyond weight loss curves
The most heavily attended morning session, "Incretin Biology at Scale," did not center on celebrity trial percentages. Instead, speakers walked through receptor signaling bias, downstream cAMP versus β-arrestin recruitment, and the implications for tissue-selective effects in liver, hypothalamus, and skeletal muscle. A recurring slide in multiple talks compared semaglutide, tirzepatide, and investigational triple agonists not on headline efficacy alone but on time-to-nadir appetite scores and durability after dose escalation hold periods.
Dr. Helena Cho, a metabolic pharmacologist presenting work from a multi-site academic consortium, argued that "the peptide sequence is only half the story—acylation site, linker chemistry, and depot behavior determine whether your animal model translates at all." Her group showed stability data for several GLP-1 analogs stored at 4 °C versus room temperature over twelve weeks, with oxidative degradants appearing on LC-MS before any visible change in lyophilized cake morphology. The audience questions ran twenty minutes over schedule.
Poster halls: lean mass, liver fat, and combination protocols
Poster section P-412 through P-489, unofficially nicknamed "the GLP-1 corridor" by attendees, featured more than seventy preclinical studies. Three themes recurred:
- Lean-mass preservation. Multiple rodent groups co-administered GLP-1 agonists with anabolic adjuvants, ketone esters, or exercise mimetics, trying to decouple fat loss from grip-strength decline. None claimed a complete fix, but several showed partial rescue of soleus muscle cross-sectional area.
- MASLD endpoints. Liver fat fraction measured by MRI declined in several primate cohorts treated with dual agonists, independent of weight normalization speed—supporting liver-directed mechanisms that laboratory teams are now trying to replicate in cell models.
- Formulation stress tests. At least nine posters documented peptide aggregation after repeated needle puncture of rubber stoppers, or after agitation in bacteriostatic water diluents at non-recommended concentrations—directly relevant to groups designing in vitro stability protocols.
A late-breaking abstract comparing head-to-head receptor occupancy models for tirzepatide and a glucagon-inclusive triple agonist drew a standing-room crowd. The authors cautioned that receptor occupancy does not equal functional potency when receptor internalization rates differ—a nuance that matters for anyone purchasing research peptides to build receptor assays rather than to treat patients.
Industry corridor: what buyers were asking
Conversations on the exhibition floor—not peer-reviewed, but indicative—suggested procurement teams are tightening specifications on research-grade incretin analogs. Common requests included: orthogonal identity confirmation (LC-MS plus peptide mapping), explicit DMF and acetonitrile residual solvent reporting, and lot-matched stability notes for reconstituted solutions at 2–8 °C.
One CRO business development manager, speaking on background, said his clients "stopped accepting a single HPLC purity number without a related-substances profile." Another noted that demand for triple-agonist research materials remains limited to reference-standard quantities until published synthetic routes stabilize—but that inquiry volume had tripled since Q1 2026.
Outlook for the second half of 2026
ENDO 2026 did not settle the competitive ranking among incretin-class peptides; Phase 3 readouts and regulatory filings scheduled for July and August were already on everyone's calendars. What the meeting did clarify is that the scientific conversation has shifted from "do these peptides work?" to "how do we characterize, combine, and responsibly supply them for rigorous study?"
For Radiptide customers, the practical lesson is straightforward: treat catalog peptides as critical reagents with the same documentation discipline expected of pharmaceutical starting materials—COA review, cold-chain verification, and institutional oversight for every in vitro or laboratory protocol. Our products are sold for research use only and are not intended for human or veterinary administration.